eligibility_summary
Adults (≥18) with MM after IMiD, PI, CD38 mAb who got ide-cel 1–3 mo prior, no progression, ECOG 0–1, ≤G1 tox, no CRS/ICANS, no intervening therapy, adequate counts, renal CrCl/eGFR ≥30, hepatic ok, O2 ≥92%, LVEF ≥45%, contraception. Exclude prior GPRC5D therapy, recent T‑cell redirect/chemo/mAb/RT/surgery/vaccines/plasmapheresis, SCT, high-dose steroids, CNS disease, cardiac/autoimmune disease, uncontrolled infection, HBV/HCV/HIV+, other cancers, pregnancy, allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm study testing talquetamab as consolidation after BCMA CAR T (idecabtagene vicleucel, ide-cel) in relapsed/refractory multiple myeloma. Intervention: subcutaneous talquetamab, a bispecific T‑cell–engaging antibody (CD3×GPRC5D) given until progression. Mechanism: binds CD3 on T cells and GPRC5D on malignant plasma cells to redirect T‑cell cytotoxicity, activating TCR/CD3 signaling, immune synapse formation, and cytokine-mediated killing. Targets: GPRC5D on myeloma plasma cells, CD3 on T cells. Context: follows prior BCMA-targeted CAR T, aims to maintain/deepen response via GPRC5D-directed immunotherapy.